Skip to main content
The Journal of Physiology logoLink to The Journal of Physiology
. 2010 Dec 15;588(Pt 24):4855–4856. doi: 10.1113/jphysiol.2010.202556

Physiological versus pathological cardiac electrical remodelling: potential basis and relevance to clinical management

Patrice Naud 1, Eduard Guasch 1, Stanley Nattel 1
PMCID: PMC3020321  PMID: 21173087

Cardiac hypertrophy is an adaptive response to haemodynamic stress. Pressure and/or volume overload in hypertension, myocardial infarction (MI) and valvular heart disease are pathological stresses that lead to left-ventricular (LV) dilatation and/or wall thickening. While in the short term compensatory mechanisms maintain cardiac output, sustained hypertrophic responses can lead to maladaptive remodelling, predisposing to cardiac arrhythmias and heart failure.

Physical exercise and pregnancy are examples of physiological stress. The nature of the exercise determines the balance between dilatation and increased wall thickness, producing so-called physiological hypertrophy. Although similar degrees of LV hypertrophy are achieved in pathological and physiological hypertrophy, physiological hypertrophy generally fails to produce adverse consequences like ventricular arrhythmias (Viitasalo et al. 1982; Biffi et al. 2008).

So, what makes the consequences of physiological remodelling different from those of pathological remodelling?

Mechanisms of stress-related cardiac remodelling

Stress alters cardiac gene expression, remodelling the structural, functional and electrophysiological properties of the heart (Nattel et al. 2010). Remodelling affects cardiomyocytes, interstitial matrix, fibroblasts and the coronary vasculature, but the molecular and cellular events underlying decompensation are poorly understood (Armoundas et al. 2001).

Heart failure is associated with upregulation of myocardial fetal and stretched-response genes (Butter et al. 2008), and numerous targets and regulators controlling hypertrophy, including phosphoinositol-3-kinase (PI3K), calcineurin, microRNAs and gene mutations are recognized (Rohini et al. 2010). Alterations in ion channels, connexins and ion transporters lead to arrhythmogenesis (Nattel et al. 2010; Roden & Kupershmidt, 1999). The characteristic changes in cells and tissues from failing hearts are action potential (AP) duration (APD) prolongation and conduction slowing (Aiba & Tomaselli, 2010). APD prolongation results principally from K+ current downregulation and typically leads to arrhythmias by inducing afterdepolarizations (Nattel et al. 2007). Heart failure also profoundly dysregulates Ca2+-handling genes and proteins, increasing Na+/Ca2+ exchange, decreasing sarcoplasmic reticulum Ca2+-ATPase and impairing Ca2+-release channel (RyR2a) function (Nattel et al. 2007). The mechanisms underlying ion channel remodelling in physiological hypertrophy are much less well understood. Regional differences in K+ current adaptation have been suggested (Stones et al. 2009).

In this issue of The Journal of Physiology, Yang et al. (2010) investigate the ionic remodelling caused by physiological hypertrophy in two mouse models. They show that mice subjected to a swimming programme develop significant ionic remodelling. With the hypertrophic process almost all currents increase substantially in amplitude, but because of parallel increases in cell size current density, the primary factor controlling transmembrane voltage (Nattel, 2008), is unaltered or moderately increased. Because relatively similar increases occur in repolarizing K+ currents and depolarizing Ca2+ current, repolarization indices remain unchanged. Similar results occur in a transgenic model of physiological hypertrophy, constitutively-active PI3K-p110a overexpression.

Different cardiac PI3K isoforms have distinct roles (Damilano et al. 2010). PI3K mediates cardiac hypertrophy, both in physiological (through PI3Kα, e.g. in exercise training) and pathological (through PI3Kγ, e.g. in pressure overload) conditions. Physiological hypertrophy is mediated primarily by the insulin-like growth factor-1 pathway, coupled with PI3Kα, and is triggered by tyrosine-kinase receptors. PI3Kα protects from fetal gene re-expression. PI3Kα inhibits apoptotic cell death by activating Akt (Dhanasekaran et al. 2008), which also suppresses pathological signalling cascades (Owen et al. 2009). The results of Yang et al. nicely link the cardioprotective effect of PI3Kα to physiological ion current remodelling. In contrast, G protein-coupled receptor (GPCR) stimulation by angiotensin II, endothelin-1 and catecholamines activates PI3Kγ, leading to pathological hypertrophy (Owen et al. 2009).

Clinical relevance of understanding electrical remodelling in physiological hypertrophy

Sudden arrhythmic death is a major cause of mortality in patients with heart failure, and repolarization abnormalities are an important predictor (Galinier et al. 1998). The observations of Yang et al. agree with the lack of repolarization changes in healthy individuals subjected to light exercise (Rajappan et al. 2003). Correspondingly, ventricular arrhythmias are not related to LV hypertrophy in athletes (Biffi et al. 2008).

The benign properties of physiological ion channel remodelling raise the attractive possibility of counteracting pathological electrophysiological adaptation and decreasing arrhythmia risk in heart disease patients by means of exercise training. Lachance et al. (2009) demonstrated a lower sudden-death rate in rats with heart failure and LV hypertrophy who were submitted to treadmill training. In rats with previous MI, normalization of APD abnormalities by exercise training has been reported (Zhang et al. 2001), although this is not a uniform finding (Bito et al. 2010). Exercise training can favourably alter signalling pathways involved in adverse cardiac remodelling (Guasch et al. 2010), and repolarization abnormalities in heart failure patients are improved by aerobic exercise training (Ali et al. 1999).

Knowledge of the pathways involved in physiological versus pathological remodelling may help in designing innovative therapeutic paradigms. Activation of the PI3Kα system, demonstrated by Yang et al. to be central to the balanced electrical remodelling seen with physiological hypertrophy, could be an interesting strategy for preventing the pathological electrical remodelling that leads to sudden death in heart disease patients. Possible approaches could run from the simplest physiological methods (e.g. exercise training) to small-molecule activators or even gene-therapy techniques. Further comparisons between signalling pathways in pathological versus physiological remodelling may provide indications of additional promising molecular targets for sudden-death prevention.

Yang et al. carefully studied remodelling of ionic currents and APs by exercise training. However, arrhythmogenesis is determined not only by cardiomyocyte cellular electrophysiology, but also by additional factors such as cardiac structure (Burstein & Nattel, 2008; Saffitz et al. 2010) and autonomic tone (Chen et al. 2007). These factors may also be influenced by exercise training, and in some circumstances may not have totally benign consequences. Right-ventricular structural remodelling may contribute to an increased incidence of ventricular arrhythmias in trained endurance athletes (Benito et al. 2010). While protecting from ventricular arrhythmias in ischaemic myocardium (Tsutsumi et al. 2008), exercise-induced autonomic-tone changes may contribute to the well-recognized occurrence of atrial fibrillation in otherwise-healthy endurance athletes (Benito et al. 2009).

Finally, it may not be accurate to assume that all forms of ‘physiological remodelling’ are necessarily equivalent. The type and intensity of exercise training may be of critical importance for ion-channel remodelling. Swimming and treadmill training induce differential responses in rats, with swimming causing a greater resting bradycardia and increased cardiac-tissue adrenaline and noradrenaline concentrations compared to running (Geenen et al. 1988). Unlike the paradigm studied by Yang et al., high-intensity exercise training can produce QT-interval prolongation reflecting ventricular repolarization delays (Sharma et al. 1999).

In conclusion, the elegant study by Yang et al. provides important and clinically relevant information about the electrophysiological changes and cell-signalling events induced by physiological remodelling. At the same time their work raises thought-provoking questions that will need to be addressed in future research.

Acknowledgments

Research support in this area is provided to S.N. by the Canadian Institutes of Health Research (MOP 44365, MOP 68929), by the MITACS Network and by the Fondation Leducq (ENAFRA Network, 07/CVD/03). E.G. is a recipient of a Rio Hortega grant from Instituto de Salud Carlos III (CM08/00201).

References

  1. Aiba T, Tomaselli GF. Curr Opin Cardiol. 2010;25:29–36. doi: 10.1097/HCO.0b013e328333d3d6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ali A, Mehra MR, Malik FS, Lavie CJ, Bass D, Milani RV. Chest. 1999;116:83–87. doi: 10.1378/chest.116.1.83. [DOI] [PubMed] [Google Scholar]
  3. Armoundas AA, Wu R, Juang G, Marban E, Tomaselli GF. Pharmacol Ther. 2001;92:213–230. doi: 10.1016/s0163-7258(01)00171-1. [DOI] [PubMed] [Google Scholar]
  4. Benito B, Cardin S, Gay G, Guasch E, Shi Y, Lawler P, Maguy A, Tardif JC, Serrano-Mollar A, Mont L, Nattel S. Circulation. 2009;120:S665–S666. [Google Scholar]
  5. Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif JC, Brugada J, Nattel S, Mont L. Circulation. 2010 doi: 10.1161/CIRCULATIONAHA.110.938282. (in press) [DOI] [PubMed] [Google Scholar]
  6. Biffi A, Maron BJ, Di GB, Porcacchia P, Verdile L, Fernando F, Spataro A, Culasso F, Casasco M, Pelliccia A. Am J Cardiol. 2008;101:1792–1795. doi: 10.1016/j.amjcard.2008.02.081. [DOI] [PubMed] [Google Scholar]
  7. Bito V, de Waard MC, Biesmans L, Lenaerts I, Ozdemir S, van DE, Abdel-Mottaleb Y, Driesen R, Holemans P, Duncker DJ, Sipido KR. Cardiovasc Res. 2010;86:72–81. doi: 10.1093/cvr/cvp381. [DOI] [PubMed] [Google Scholar]
  8. Burstein B, Nattel S. J Cardiovasc Pharmacol. 2008;5:782–796. doi: 10.1097/FJC.0b013e3181668057. [DOI] [PubMed] [Google Scholar]
  9. Butter C, Rastogi S, Minden HH, Meyhofer J, Burkhoff D, Sabbah HN. J Am Coll Cardiol. 2008;51:1784–1789. doi: 10.1016/j.jacc.2008.01.036. [DOI] [PubMed] [Google Scholar]
  10. Chen LS, Zhou S, Fishbein MC, Chen PS. J Cardiovasc Electrophysiol. 2007;18:123–127. doi: 10.1111/j.1540-8167.2006.00590.x. [DOI] [PubMed] [Google Scholar]
  11. Damilano F, Perino A, Hirsch E. Ann N Y Acad Sci. 2010;1188:39–45. doi: 10.1111/j.1749-6632.2009.05081.x. [DOI] [PubMed] [Google Scholar]
  12. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, Zhang R, Gross GJ, Falck JR, Patel PK, Jacobs ER, Medhora M. Am J Physiol Heart Circ Physiol. 2008;294:H724–H735. doi: 10.1152/ajpheart.00979.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Galinier M, Vialette JC, Fourcade J, Cabrol P, Dongay B, Massabuau P, Boveda S, Doazan JP, Fauvel JM, Bounhoure JP. Eur Heart J. 1998;19:1054–1062. doi: 10.1053/euhj.1997.0865. [DOI] [PubMed] [Google Scholar]
  14. Geenen D, Buttrick P, Scheuer J. J Appl Physiol. 1988;65:116–123. doi: 10.1152/jappl.1988.65.1.116. [DOI] [PubMed] [Google Scholar]
  15. Guasch E, Benito B, Nattel S. J Physiol. 2010;588:2525–2526. doi: 10.1113/jphysiol.2010.194134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lachance D, Plante E, Bouchard-Thomassin AA, Champetier S, Roussel E, Drolet MC, Arsenault M, Couet J. Circ Heart Fail. 2009;2:437–445. doi: 10.1161/CIRCHEARTFAILURE.108.845487. [DOI] [PubMed] [Google Scholar]
  17. Nattel S. Circ Res. 2008;102:1298–1300. doi: 10.1161/CIRCRESAHA.108.178087. [DOI] [PubMed] [Google Scholar]
  18. Nattel S, Frelin Y, Gaborit N, Louault C, Demolombe S. J Mol Cell Cardiol. 2010;48:96–105. doi: 10.1016/j.yjmcc.2009.07.016. [DOI] [PubMed] [Google Scholar]
  19. Nattel S, Maguy A, Le BS, Yeh YH. Physiol Rev. 2007;87:425–456. doi: 10.1152/physrev.00014.2006. [DOI] [PubMed] [Google Scholar]
  20. Owen KL, Pretorius L, McMullen JR. Clin Sci (Lond) 2009;116:365–375. doi: 10.1042/CS20080183. [DOI] [PubMed] [Google Scholar]
  21. Roden DM, Kupershmidt S. Cardiovasc Res. 1999;42:318–326. doi: 10.1016/s0008-6363(99)00063-2. [DOI] [PubMed] [Google Scholar]
  22. Rohini A, Agrawal N, Koyani CN, Singh R. Pharmacol Res. 2010;61:269–280. doi: 10.1016/j.phrs.2009.11.012. [DOI] [PubMed] [Google Scholar]
  23. Rajappan K, O'Connell C, Sheridan DJ. Int J Cardiol. 2003;87:217–22. doi: 10.1016/s0167-5273(02)00326-1. [DOI] [PubMed] [Google Scholar]
  24. Saffitz JE, Asimaki A, Huang H. Cardiovasc Pathol. 2010;19:166–70. doi: 10.1016/j.carpath.2009.10.006. [DOI] [PubMed] [Google Scholar]
  25. Sharma S, Whyte G, Elliott P, Padula M, Kaushal R, Mahon N, McKenna WJ. Br J Sports Med. 1999;33:319–324. doi: 10.1136/bjsm.33.5.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stones R, Billeter R, Zhang H, Harrison S, White E. Basic Res Cardiol. 2009;104:643–652. doi: 10.1007/s00395-009-0030-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tsutsumi T, Ide T, Yamato M, Kudou W, Andou M, Hirooka Y, Utsumi H, Tsutsui H, Sunagawa K. Cardiovasc Res. 2008;77:713–721. doi: 10.1093/cvr/cvm092. [DOI] [PubMed] [Google Scholar]
  28. Viitasalo MT, Kala R, Eisalo A. Br Heart J. 1982;47:213–220. doi: 10.1136/hrt.47.3.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Yang KC, Foeger NC, Marionneau C, Jay PY, McMullen JR, Nerbonne JM. J Physiol. 2010;588:5015–5032. doi: 10.1113/jphysiol.2010.197418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zhang XQ, Zhang LQ, Palmer BM, Ng YC, Musch TI, Moore RL, Cheung JY. J Appl Physiol. 2001;90:1720–1728. doi: 10.1152/jappl.2001.90.5.1720. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Physiology are provided here courtesy of The Physiological Society

RESOURCES